Our thorough transcriptional analysis identified further molecular interactions with the MYC transcriptional network, supported by additional analysis of clinical data, showing CLL patients with high PRMT5 expression to display enhanced MYC activity. The gene discussed is PRMT5; the disease is B-cell chronic lymphocytic leukemia.